Exploring the intricate connection between genetics and cardiovascular health, cardiovascular pharmacogenomics stands at the forefront of medical innovation. This field delves into the genetic factors influencing how individuals respond to cardiovascular drugs, with a primary objective of fine-tuning treatment outcomes and mitigating potential adverse effects. Through a comprehensive analysis of genetic variations impacting drug metabolism, efficacy, and toxicity, cardiovascular pharmacogenomics endeavors to customize medication regimens based on each patient's distinct genetic profile. This personalized approach not only holds the potential to optimize the effectiveness of cardiovascular therapies but also aims to minimize the occurrence of side effects, thereby elevating overall patient outcomes. In an era of advancing genomic understanding, cardiovascular pharmacogenomics emerges as a pivotal player in the ongoing evolution toward precision medicine, paving the way for more nuanced and targeted treatments in the realm of cardiovascular diseases.
Title : Revolutionizing CKD care: How finerenone transforms outcomes in heart and kidney health - Insights from fidelio-DKD
Robert J Chilton, University of Texas Health Science Center San Antonio, United States
Title : Novel important cellular responses, signaling mechanisms and therapeutic options for pulmonary hypertension and right heart failure
Yong Xiao Wang, Albany Medical Center, United States
Title : Preventing sports-related cardiac arrest: Coronary artery calcium scoring stratifies the benefit of low-dose aspirin use for risk reduction
Arthur J Siegel, Massachusetts General Hospital, United States
Title : Empathy and precision: Revolutionizing communication between cardiologists and patients
Iris Panagiota Efthymiou, University of Greenwich, United Kingdom
Title : Post-cardiotomy ECMO (PC-ECMO)
Gustavo Lionel Knop, Mayo Clinic, United States
Title : The past, present and future of AI in cardiology
Narendra Kumar, HeartbeatsZ Academy, United Kingdom